

BioSenic
Public limited liability company
Rue Granbonpré 11, Building H
1435 Mont-Saint-Guibert
RLE Walloon Brabant
VAT : BE0882.015.654
(the "Company")

**INFORMATION CONCERNING THE RIGHTS OF SHAREHOLDERS PURSUANT TO
ARTICLES 7:130 AND 7:139 OF THE BELGIAN CODE ON COMPANIES AND ASSOCIATIONS
ON THE OCCASION OF THE ORDINARY GENERAL MEETING OF THE COMPANY TO BE
HELD ON 14 JUNE 2023 AS OF 4:00 P.M. (BELGIAN TIME) AT THE OFFICES OF OSBORNE
CLARKE, BASTION TOWER, PLACE DU CHAMP DE MARS 5, 1050 BRUSSELS**

1. RIGHT OF SHAREHOLDERS TO PLACE ITEMS ON THE AGENDA AND TO SUBMIT PROPOSALS FOR DECISIONS

In accordance with article 7:130 of the Belgian Code on Companies and Associations, one or more shareholders who together hold at least 3% of the capital may (i) request the inclusion of matters to be dealt with on the agenda of the ordinary general meeting, as well as (ii) submit proposals for resolutions regarding matters to be dealt with that have been included or are to be included in the agenda.

The shareholder(s) exercising this right must, in order for their request to be dealt with at the ordinary general meeting, fulfil the following two conditions:

- prove that they hold the percentage set out above at the date of their request (either with a certificate showing the registration of the corresponding shares in the Company's share register, or with a certificate delivered by the licensed account holder or the settlement institution certifying the registration in their name of the corresponding number of dematerialised shares); and
- still be shareholder(s) above the 3% threshold at the record date (on **31 May 2023** at midnight (Belgian time)).

Shareholders may then exercise their right by submitting (i) the draft new items for the agenda, and/or (ii) the draft proposals for resolution to be reflected in the agenda by e-mail to generalassembly@biosenic.com or by letter to the attention of BioSenic, Mr Benjamin D'Haese, Rue Granbonpré 11, Building H, 1435 Mont-Saint-Guibert, Belgium, on **23 May 2023** at the latest. The Company will acknowledge receipt of requests made by e-mail or letter to the address indicated by the shareholder within 48 hours of such receipt.

The Company will publish the revised agenda, on **30 May 2023** at the latest (on the website of the Company at the address www.biosenic.com, in the Belgian Official Gazette and in the press) if one or more requests to add new items or proposals for decisions to the agenda have been validly received within the abovementioned period.

The *ad hoc* proxy form with the items to be dealt with and/or the proposals for decisions will be made available on the website of the Company at the address www.biosenic.com, at the same time as the publication of the revised agenda, i.e. on **30 May 2023** at the latest.

However, proxies notified to the Company before the publication of a revised agenda shall remain valid for the items of the agenda they cover. As an exception to the above, for items of the agenda which are the subject of proposals for new resolutions submitted pursuant to article 7:130 of the Belgian Code on Companies and

Associations, the proxy holder may, during the ordinary general meeting, deviate from any instructions given by the proxy grantor if the execution of these instructions would prejudice the interests of the proxy grantor. The proxy holder must inform the proxy grantor of this. The proxy grantor must indicate whether the proxy holder is entitled to vote on the new items of the agenda or whether the proxy holder should abstain.

2. RIGHT OF SHAREHOLDERS TO ASK QUESTIONS IN WRITING

In accordance with article 7:139 of the Belgian Code on Companies and Associations, shareholders have the right to ask questions in writing to the directors and/or the auditor prior to the ordinary general meeting to be held on **14 June 2023**.

The exercise of this right is subject to the following two conditions:

- being a shareholder on the record date (**31 May 2023**, at midnight (Belgian time)); and
- having informed the Company of the intention to participate in the ordinary general meeting, in accordance with the provisions set out in the convening notice.

These questions can be submitted prior to the ordinary general meeting by e-mail to generalassembly@biosenic.com or by letter to the attention of BioSenic, Mr Benjamin D'Haese, Rue Granbonpré 11, Building H, 1435 Mont-Saint-Guibert, Belgium. They must be received by the Company no later than on **8 June 2023** at 5:00 p.m. (Belgian time).

During the ordinary general meeting, the directors shall answer questions raised by the shareholders, in writing before the meeting or orally at the meeting, regarding their reports or the items of the agenda, provided that the disclosure of certain data or facts shall not be prejudicial to the Company or to the confidentiality undertakings given by the Company or its directors. The auditor shall also answer questions raised by the shareholders, either at the meeting or in writing before the meeting, concerning his reports.

The directors may give a global answer to several questions on the same subject.